{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:41:40Z","timestamp":1777927300804,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T00:00:00Z","timestamp":1581206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>We report the use of crushed dolutegravir (DTG) and tenofovir alafenamide (TAF) tablets in a 27-year-old man with progressive dysphagia due to eosinophilic esophagitis, which severely limited compliance, leading to viral resistance. Based on his drug resistance history, allergies, and inability to swallow tablets intact, he was transitioned to DTG 50\u2009mg (crushed), TAF 25\u2009mg (crushed), liquid abacavir (20\u2009mg\/ml) 30\u2009ml, and liquid emtricitabine (10\u2009mg\/ml) 24\u2009ml orally daily. After receiving this regimen for five months, the patient\u2019s HIV viral load decreased from 9910 to 59\u00a0copies\/ml and after ten total months became suppressed at &lt;20\u00a0copies\/ml. Our case report suggests administration of crushed DTG and TAF tablets may be a viable option for patients with dysphagia and limited treatment options.<\/jats:p>","DOI":"10.1177\/0956462419895690","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:28:56Z","timestamp":1581294536000},"page":"285-287","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-2735","authenticated-orcid":false,"given":"Sarah E","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Franciscan Health Indianapolis, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Huesgen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Indiana University Health, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Howe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Indiana University Health, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,9]]},"reference":[{"key":"bibr1-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1177\/2325957417692678"},{"key":"bibr2-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1960"},{"key":"bibr3-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky191"},{"key":"bibr4-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418797847"},{"key":"bibr5-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.632"},{"key":"bibr6-0956462419895690","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160102"},{"key":"bibr7-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1502863"},{"key":"bibr8-0956462419895690","volume-title":"Ritonavir (package insert","author":"AbbVie Inc.","year":"2017"},{"key":"bibr9-0956462419895690","unstructured":"AIDSinfo. Ritonavir, https:\/\/aidsinfo.nih.gov\/drugs\/244\/ritonavir\/33\/professional (accessed November 2019)."},{"key":"bibr10-0956462419895690","unstructured":"European Medicines Agency. Vemlidy, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vemlidy#product-information-section (accessed January 2019)."},{"key":"bibr11-0956462419895690","volume-title":"Vemlidy (package insert)","author":"Gilead Sciences.","year":"2018"},{"key":"bibr12-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1835"},{"key":"bibr13-0956462419895690","unstructured":"U.S. Food and Drug Administration. Drugs@FDA database, https:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/ (accessed January 2019)."},{"key":"bibr14-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05739-11"},{"key":"bibr15-0956462419895690","volume-title":"Tivicay (package insert)","author":"GlaxoSmithKline","year":"2013"},{"key":"bibr16-0956462419895690","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31821b42d1"},{"key":"bibr17-0956462419895690","doi-asserted-by":"publisher","DOI":"10.2165\/11318110-000000000-00000"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462419895690","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462419895690","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462419895690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:40:16Z","timestamp":1777675216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462419895690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1177\/0956462419895690"],"URL":"https:\/\/doi.org\/10.1177\/0956462419895690","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,9]]}}}